NOURIANZ (istradefylline)
ANTIPARKINSON ADJUVANT - ADENOSINE RECEPTOR ANTAGONIST · IDIOPATHIC PARKINSONISM
KYOWA KIRIN, IN
Drug class
Antiparkinson Adjuvant - Adenosine Receptor Antagonist
The therapeutic class antiparkinson adjuvant - adenosine receptor antagonist encompasses non-dopaminergic agents—most notably the selective adenosine A2A receptor antagonist istradefylline—used alongside foundational dopaminergic therapy. Read more about Antiparkinson Adjuvant - Adenosine Receptor Antagonist
1 drugs in this class 1 manufacturers
Drugs in Antiparkinson Adjuvant - Adenosine Receptor Antagonist
Filter & compare in the drug finder →
Opens the drug finder with Antiparkinson Adjuvant - Adenosine Receptor Antagonist preselected. Add indication or manufacturer filters there.
The therapeutic class antiparkinson adjuvant - adenosine receptor antagonist encompasses non-dopaminergic agents—most notably the selective adenosine A2A receptor antagonist istradefylline—used alongside foundational dopaminergic therapy.
These medications function by selectively blocking adenosine A2A receptors abundantly located in the basal ganglia, thereby modulating indirect pathway neurotransmission and facilitating basal ganglia motor signaling without directly stimulating dopamine receptors.
Clinically, this class is utilized in Parkinson's disease as an adjunctive treatment to carbidopa/levodopa regimens to reduce the duration and frequency of motor fluctuations, commonly referred to as "off" episodes.
-
berkeley.edu
The therapeutic class antiparkinson adjuvant - adenosine receptor antagonist encompasses non-dopaminergic agents—most notably the selective adenosine A2A receptor antagonist istradefylline—used alongside foundational dopaminergic therapy
-
wikipedia.org
The therapeutic class antiparkinson adjuvant - adenosine receptor antagonist encompasses non-dopaminergic agents—most notably the selective adenosine A2A receptor antagonist istradefylline—used alongside foundational dopaminergic therapy These medications function by selectively blocking adenosine A2A receptors abundantly located in the basal ganglia, thereby modulating indirect pathway neurotransmission and facilitating basal ganglia motor signaling without directly stimulating dopamine recepto...
-
fda.gov
These medications function by selectively blocking adenosine A2A receptors abundantly located in the basal ganglia, thereby modulating indirect pathway neurotransmission and facilitating basal ganglia motor signaling without directly stimulating dopamine receptors
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.